Full Text:   <2185>

CLC number: R737.9

On-line Access: 

Received: 2003-06-13

Revision Accepted: 2003-11-03

Crosschecked: 0000-00-00

Cited: 11

Clicked: 6023

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE A 2004 Vol.5 No.4 P.472-476

http://doi.org/10.1631/jzus.2004.0472


Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity


Author(s):  HAN Ming-yong, ZHENG Shu, YU Jin-ming, PENG Jia-ping, GUO Qi-sen, WANG Jia-lin

Affiliation(s):  Cancer Institute,Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; more

Corresponding email(s):   Zhengshu@mail.hz.zj.cn

Key Words:  Interleukin-18, Breast cancer, Transfection, Tumorigenesis


Share this article to: More

HAN Ming-yong, ZHENG Shu, YU Jin-ming, PENG Jia-ping, GUO Qi-sen, WANG Jia-lin. Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity[J]. Journal of Zhejiang University Science A, 2004, 5(4): 472-476.

@article{title="Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity",
author="HAN Ming-yong, ZHENG Shu, YU Jin-ming, PENG Jia-ping, GUO Qi-sen, WANG Jia-lin",
journal="Journal of Zhejiang University Science A",
volume="5",
number="4",
pages="472-476",
year="2004",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2004.0472"
}

%0 Journal Article
%T Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity
%A HAN Ming-yong
%A ZHENG Shu
%A YU Jin-ming
%A PENG Jia-ping
%A GUO Qi-sen
%A WANG Jia-lin
%J Journal of Zhejiang University SCIENCE A
%V 5
%N 4
%P 472-476
%@ 1869-1951
%D 2004
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2004.0472

TY - JOUR
T1 - Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity
A1 - HAN Ming-yong
A1 - ZHENG Shu
A1 - YU Jin-ming
A1 - PENG Jia-ping
A1 - GUO Qi-sen
A1 - WANG Jia-lin
J0 - Journal of Zhejiang University Science A
VL - 5
IS - 4
SP - 472
EP - 476
%@ 1869-1951
Y1 - 2004
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2004.0472


Abstract: 
To study the effect of interleukin-18 gene transfection on the tumorigenesis of breast cancer cell line Bacp37, human breast cancer cell line Bcap37 were transfected with Lipofectamine and selected by G418. The biological expression of rhIL-18 was tested by RT-PCR and ELISA method; nude mice were injected with Bcap37 cell with or without the hIL-18 gene. The hIL-18 cDNA was successfully integrated into Bcap37 cell; 126.3±4.5 pg hIL-18 secreted by one million transduced cells in 24 hours. Nude mice injected with IL-18 gene engineered Bcap37 cell had no tumor growth. These findings indicated that human breast cancer cells were successfully modified by the gene of IL-18 cytokine; the IL-18 gene engineered Bcap37 cells secreted hIL-18 and lost their tumorigenicity. The Bcap37 cells transduced with IL-18 gene may be used as breast cancer vaccine.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Dao, T., Mehal, W.Z., Crispe, I.N., 1998. IL-18 augmens perforin-dependent cytotoxicity of liver NK-T cells.J. Immnol,61:2217-2222.

[2] Hashimoto, W., Oksaki, T., Okamura, H., Robbins, P.D., Kurimoto, M., Nagata, S., Lotze, M.T, Tahara, H., 1999. Differential antitumor effects of administration of rIL-18 or RIL-12 are mediated primarily by Fas-Fas Ligand- and perforin-induced tumor apoptosis, respectively.J. Immunol,163:583-589.

[3] Micallef, M.J., Tanimoto, T., Kohno, K., Ikeda, M., Kurimoto, M., 1997a. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.Cancer Res.,57:4557-4563.

[4] Micallef, M.J., Yoshida, K., Kawai, S., Hanaya, T., Kohno, K., Arai, S., Tanimoto, T., Torigoe, K., Fujii, M., Ikeda, M., Kurimoto, M., 1997b. In vivo antitunor effects of murine IFN-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites.Cancer Immunol. Immunother,43:361-367.

[5] Okamoto, I., Kohno, K., Tanimoto, T., Ikegami, H., Kurimoto, M., 1999. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12.J. Immunol,162:3202-3211.

[6] Okamura, H., Nagata, K., Komatsu, T., Nukata, Y., Tanabe, F., Akita, K., Torigoe, K., Okura, T., Fukuda, S., Kurimoto, M., 1995a. A novel costimulatory factor for γ interferon induction found in the livers of mice causes endotoxic shock.Infect. Immun.,63:3966-3972.

[7] Okamura, H., Tsutsi, H., Komatsus, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., 1995b. Cloning of a new cytokine that induces IFN-gamma production by T cells.Nature,378:88-91.

[8] Osaki, T., Peron, J.M., Cai, Q., Okamura, H., Robbins, P.D., Kurimoto, M., Lotze, M.T., Tahara, H., 1998. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ-and IL-12-independent antitumor effects.J. Immunol,160:1742-1749.

[9] Osaki, T., Hashimoto, W., Gambotto, A., Okamura, H., Robbins, P.D., Kurimoto, M., Lotze, M.T., Tahara, H., 1999. Potent antitumor effects mediated by local expression of the mature form of the IFN-γ-inducing factor, interleukin-18 (IL-18).Gene Ther,6:808-815.

[10] Pages, F., Berger, A., Henglein, B., Piqueras, B., Danel, C., Zinzindahooouse, F., Thiounn, N., Cagnenc, P.H., Fridman, W.H.,1999. Modulation of interleukin-18 expression expression in human colon carcinoma: consequence for tumor immune surveillance.Int J Cancer,84(3):13962-13966.

[11] Robinson, D., Shibuya, K., Mui, A., Zonin, F., Murphy, E., Sana, T., Hartley, S.B., Menon, S., Kastelein, R., Bazan, F., O'Garra, A., 1997. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NF kappaB.Immunity,7(4):571-581.

[12] Takeda, K., Tsutsui, H., Yoshimoto, T., Adachi, O., Yoshida, N., Kishimoto, T., Okamura, H., Nakanishi, K., Akira, S., 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice.Immunol,8:383-390.

[13] Tasaki, K., Yoshida, Y., Maede, T., Miyauchi, M., Kawamura, K., Takenaga, K., Yamamoto, H., Kouzu, T., Asano, T., Ochiai, T., Sakiyama, S., Tagawa, M., 2000. Protective immunity is induced in murine colon carcin-oma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells.Cancer Gene Ther,7:247-254.

[14] Ushio, S., Namba, M., Okura, T., Hattori, K., Nukada, Y., Akita, K., Tanabe, F., Konishi, K., Micallef, M., Fujii, M., Torigoe, K., Tanimoto, T., Fukuda, S., Ikeda, M., Okamura, H., Kurimoto, M., 1996. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein.J. Immunol,156:4274-4279.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE